Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS - Science Translational Medicine
- Commentary & Opinion
- Regulation and Clinical Evidence
Summary:
The authors propose the concept of “evidence landscapes” as a tool for mapping and coordinating the complex evidence needed in precision medicine, where therapeutic strategies involve ensembles of diagnostic tests, biomarker validations, and targeted treatments that each require independent evaluation.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
The Impact of Semantics in Medicines Regulation
Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.